Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISOR: Vericiguat and ISMN Interaction Study
NCT03255512Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in coronary artery disease (CAD) (2 arms), sponsored by Bayer. Primary endpoints: Blood pressure at 8 weeks and Heart rate at 8 weeks. Started Aug 2017; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03255512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255512.